Enliven Therapeutics (ELVN)
NASDAQ:ELVN
US Market
Holding ELVN?
Track your performance easily

Enliven Therapeutics (ELVN) Ownership - Who Owns Enliven Therapeutics?

285 Followers

Enliven Therapeutics (ELVN) Ownership Overview

46.20%15.35%1.18%9.51%27.76%
46.20% Insiders
1.18% Other Institutional Investors
9.51% ETFs
27.76% Public Companies and
Individual Investors
The ownership structure of Enliven Therapeutics (ELVN) stock is a mix of institutional, retail, and individual investors. Approximately 26.04% of the company’s stock is owned by Institutional Investors, 46.20% is owned by Insiders, and 27.76% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
May 20, 2024
Orbimed Advisors Llc
Director, >10% Owner
xxxxxxxxxxxxx
$22877262
May 20, 2024
Rishi Gupta
Director, >10% Owner
xxxxxxxxxxxxx
$22877262
Feb 16, 2024
xxxxxxxxxxxxx
$12292500
Feb 02, 2024
xxxxxxxxxxxxx
$7500000

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2024
xxxxxxxxxxxxx
$5632
Jun 30, 2024
xxxxxxxxxxxxx
$7505976
Jun 30, 2024
xxxxxxxxxxxxx
$16884918

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
7,663,349Insider16.22%221,930,587
7,663,349Insider16.22%221,930,587
3,835,975Insider8.12%111,089,836
3,202,798Institution6.78%92,753,030
2,312,625Institution4.90%66,973,620
2,122,465Institution4.49%61,466,586
1,816,517Institution3.85%52,606,332
1,652,807Institution3.50%47,865,291
1,466,658Institution3.10%42,474,416
1,015,188Insider2.15%29,399,844

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
1,652,807Institution3.50%47,865,291
1,466,658Institution3.10%42,474,416
979,038Institution2.07%28,352,940
956,113Institution2.02%27,689,032
513,246Institution1.09%14,863,604
397,367Institution0.84%11,507,748
322,550Institution0.68%9,341,048
177,963Institution0.38%5,153,808
160,470Institution0.34%4,647,211
121,200Institution0.26%3,509,952

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,448,028Institution3.07%27,867,056
956,954Institution2.03%27,713,388
590,978Institution1.25%11,625,572
298,161Institution0.63%8,634,743
203,254Institution0.43%5,886,236
160,977Institution0.34%4,111,353
140,306Institution0.30%4,068,874
80,350Institution0.17%2,326,936
73,165Institution0.15%2,118,858
62,801Institution0.13%1,603,938

FAQ

Who Owns Enliven Therapeutics (ELVN)?
According to the latest TipRanks data, approximately 1.18% of the company's stock is held by institutional investors, 46.20% is held by insiders, and 27.76% is held by retail investors.
    What percentage of Enliven Therapeutics (ELVN) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 1.18% of Enliven Therapeutics (ELVN) stock is held by institutional investors.
      What percentage of Enliven Therapeutics (ELVN) stock is held by retail investors?
      According to the latest TipRanks data, approximately 27.76% of Enliven Therapeutics (ELVN) stock is held by retail investors.
        Who owns the most shares of Enliven Therapeutics (ELVN)?
        Rishi Gupta owns the most shares of Enliven Therapeutics (ELVN).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis